2.50
Hdl Handle:
http://hdl.handle.net/10541/92936
Title:
Papillomavirus vaccines.
Authors:
Duggan-Keen, Margaret F; Brown, Michael D; Stacey, Simon N; Stern, Peter L
Abstract:
The considerable morbidity and mortality associated with certain human papillomaviruses (HPV) has provided the impetus for HPV vaccine development. The design of such vaccines has evolved from an understanding of the nature of HPV infections and their consequences, together with evaluation of the efficacy of different approaches to vaccination in animal models. These studies have culminated in the production of several different vaccine preparations which are currently undergoing Phase I and II clinical trials. The justification for the widespread implementation of prophylactic HPV vaccines will depend on the outcome of larger scale studies of vaccine efficacy that take into account the epidemiology of HPV infections and associated disease. The usefulness of therapeutic HPV vaccines will require evidence that they can substantially augment or substitute for the effectiveness of currently available treatments.
Affiliation:
Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, United Kingdom.
Citation:
Papillomavirus vaccines. 1998, 3:D1192-208 Front. Biosci.
Journal:
Frontiers in Bioscience
Issue Date:
1-Dec-1998
URI:
http://hdl.handle.net/10541/92936
PubMed ID:
9835649
Type:
Article
Language:
en
ISSN:
1093-4715
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorDuggan-Keen, Margaret Fen
dc.contributor.authorBrown, Michael Den
dc.contributor.authorStacey, Simon Nen
dc.contributor.authorStern, Peter Len
dc.date.accessioned2010-02-24T14:08:58Z-
dc.date.available2010-02-24T14:08:58Z-
dc.date.issued1998-12-01-
dc.identifier.citationPapillomavirus vaccines. 1998, 3:D1192-208 Front. Biosci.en
dc.identifier.issn1093-4715-
dc.identifier.pmid9835649-
dc.identifier.urihttp://hdl.handle.net/10541/92936-
dc.description.abstractThe considerable morbidity and mortality associated with certain human papillomaviruses (HPV) has provided the impetus for HPV vaccine development. The design of such vaccines has evolved from an understanding of the nature of HPV infections and their consequences, together with evaluation of the efficacy of different approaches to vaccination in animal models. These studies have culminated in the production of several different vaccine preparations which are currently undergoing Phase I and II clinical trials. The justification for the widespread implementation of prophylactic HPV vaccines will depend on the outcome of larger scale studies of vaccine efficacy that take into account the epidemiology of HPV infections and associated disease. The usefulness of therapeutic HPV vaccines will require evidence that they can substantially augment or substitute for the effectiveness of currently available treatments.en
dc.language.isoenen
dc.subjectTumour Virus Infectionsen
dc.subjectUterine Cervical Canceren
dc.subject.meshAntigens, Viral-
dc.subject.meshBacteria-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDNA, Viral-
dc.subject.meshDendritic Cells-
dc.subject.meshDisease Models, Animal-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunity, Innate-
dc.subject.meshPapillomaviridae-
dc.subject.meshPapillomavirus Infections-
dc.subject.meshPapillomavirus Vaccines-
dc.subject.meshPeptides-
dc.subject.meshTumor Virus Infections-
dc.subject.meshUterine Cervical Neoplasms-
dc.subject.meshVaccines, DNA-
dc.subject.meshViral Proteins-
dc.subject.meshViral Vaccines-
dc.subject.meshVirion-
dc.titlePapillomavirus vaccines.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, United Kingdom.en
dc.identifier.journalFrontiers in Bioscienceen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.